Showing 3711-3720 of 5977 results for "".
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of at
- Lebrikizumab Maintains Efficacy Through 52 Weekshttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-through-52-weeks/2466977/New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period. “Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported ou
- Study Highlights Gaps in Dermatology PA Certification Exam Coveragehttps://practicaldermatology.com/news/research-highlights-gaps-dermatology-pa-certification-exam-coverage/2466960/New research suggests that the prevalence of skin disease burden in the United States generally aligns with the physician assistant (PA) certification exam, with areas for improvement. According to the new study published in the Journal of Dermatology Physicians Assistants, the National C
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areatahttps://practicaldermatology.com/news/equillium-announces-positive-topline-data-phase-2-study-eq101-alopecia-areata/2466936/Equillium announced positive topline data from its phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA). The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Dapsone Gel Shows Promise for Treating Acne in Skin of Colorhttps://practicaldermatology.com/news/dapsone-gel-shows-promise-treating-acne-skin-color/2463234/A new study in the Journal of Drugs in Dermatology indicates that dapsone gel, 7.5% (Aczone®, Almirall) was safe and effective in the treatment of acne vulgaris in patients with skin of color. "Acne vulgaris is a common skin disease prevalent in skin of color patients
- Survey Shows Low Awareness, High Risk of Actinic Keratosis from Sun Exposurehttps://practicaldermatology.com/news/survey-shows-low-awareness-high-risk-actinic-keratosis-sun-exposure/2463197/A recent survey conducted by Almirall showed gaps in public awareness about actinic keratosis (AK) and the associated risks of sun exposure. The survey, which included more than 2,500 participants aged 35 and older from Spain, Germany, Italy, the United Kingdom, and the United States, rev
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Alma Unveils Versatile Aesthetic Workstation and Smart Skin Analysis Systemhttps://practicaldermatology.com/news/alma-unveils-versatile-aesthetic-workstation-and-smart-skin-analysis-system/2463172/Energy-based device manufacturer Alma has introduced Alma Harmony and Alma IQ. Alma Harmony is the latest version of the company's multi-technology aesthetics workstation and is available for sale in the U.S. This system, according to a press release, builds on a 20-year legacy and is FDA